Arcutis Biotherapeutics Inc [ARQT] stock is trading at $26.17, up 4.68%. An important factor to consider is whether the stock is rising or falling in short-term value. The ARQT shares have gain 10.19% over the last week, with a monthly amount glided 25.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on July 25, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $19. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. Mizuho upgraded its rating to a Buy and increased its price target to $8 on January 03, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on October 26, 2023. Goldman downgraded its rating to Neutral for this stock on October 13, 2023, and downed its price target to $6. In a note dated September 07, 2022, Needham initiated a Buy rating and provided a target price of $46 on this stock.
Arcutis Biotherapeutics Inc [ARQT] stock has fluctuated between $8.90 and $27.08 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $26.17 at the most recent close of the market. An investor can expect a potential return of 15.9% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 317.93M for the trailing twelve months, which represents a growth of 121.69%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.3 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.06 points at the first support level, and at 23.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.05, and for the 2nd resistance point, it is at 27.93.
Ratios To Look Out For
For context, Arcutis Biotherapeutics Inc’s Current Ratio is 3.50. On the other hand, the Quick Ratio is 3.28, and the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 10.08, the price to book ratio is 19.91.
Transactions by insiders
Recent insider trading involved Krishnamohan Neha, Director, that happened on Nov 13 ’25 when 40504.0 shares were sold. Director, Neha Krishnamohan completed a deal on Nov 13 ’25 to buy 40504.0 shares. Meanwhile, Edwards Larry Todd sold 29131.0 shares on Nov 06 ’25.
